Amgen's (NAS: AMGN) cancer drug ganitumab failed a phase 3 trial, and the stock is trading up a little today.
A sign that Amgen has achieved big pharma one-drug-doesn't-matter status? A sign that investors know pancreatic cancer is a tough indication? Probably both.
Amgen didn't give many details beyond that it was stopping the trial that was comparing a combination of ganitumab and Eli Lilly's (NYS: LLY) Gemzar to Gemzar alone because it was clear the drug wasn't helping pancreatic cancer patients.
The only solace investors can take in the news is that the decision was based on a futility analysis while the trial was going on. By ending the trial early, Amgen avoids spending cash on a trial that wasn't going to work. It's also stopping a phase 2 trial in advanced pancreatic cancer.
The drug is also being tested in colorectal and small-cell lung cancer, a couple of other hard-to-treat cancers. It's all relative of course -- most cancers are hard to treat -- but pancreatic, colon, and lung cancers are near the top. Amgen's investors seem to have gotten that and not priced in success into the valuation. Investors in Celgene (NAS: CELG) , which is running a late-stage trial in pancreatic cancer, should keep that in mind.
The other side of the story is that Amgen has gotten quite large. It's actually larger by market cap than Bristol-Myers Squibb (NYS: BMY) , which we typically put in the big pharma class, and while Amgen's dividend yield is nothing to get too excited about -- no one is going to run out and buy shares for a 1.7% yield -- the dividend does offer a return even when things aren't going perfectly.
When a company gets this big, balancing where to put the cash it's bringing in becomes increasingly complex. Investors should look for the company to make strategic bets with its R&D dollars to leave as much cash as possible to return to investors through dividends and share repurchases. A few long-shots in hard-to-treat indications are OK, but Amgen needs to keep in mind what it's become.
Looking for more dividend ideas? Check out the Fool's new free report "Secure Your Future With 9 Rock-Solid Dividend Stocks." Just click here to get your free copy.
The article A Sign This Biotech Is All Grown-Up originally appeared on Fool.com.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.